MYCN and neuroblastoma: Other tumors seemed to be the result of late progression of low-risk neuroblastoma or of gene amplifications other than MYCN. This clinicogenetic diversity of unfavorable neuroblastoma is likely to reflect differences in tumor evolution and growth, which may have therapeutic implications.